Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.
Melissa L. Johnson(Tennessee Oncology), Himisha Beltran(Dana-Farber Cancer Institute), Hirva Mamdani(Wayne State University), Grace K. Dy(Roswell Park Comprehensive Cancer Center), Afshin Dowlati(University Hospitals of Cleveland), Yifah Yaron, Jose M. Pacheco(University of Colorado Cancer Center), Linda Santiago, Rachel E. Sanborn(Providence Portland Medical Center), Smitha Menon(Medical College of Wisconsin), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center)
Cited by 45
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k